- Profitable Growth Core EBITDA margin reached 23.5%, up from 17.7%, driven by operational efficiency and portfolio optimization.
- Acquisition Impact Noramco and Extractas acquisitions expected to boost 2026 top and bottom line performance significantly.
- Financial Strength Sales hit CHF 1.33 billion (+4.3% local currencies), with cash flow up 35% YoY due to disciplined working capital management.
- Strategic Flexibility Net debt-to-EBITDA ratio at 1.0x ensures financial flexibility for future investments and shareholder returns.
- 2026 Outlook High single-digit Drug Products growth and low single-digit Drug Substance growth anticipated, with core EBITDA margin above 23%.
Financial Highlights
The company's results confirmed the strength of its diversified portfolio, operational efficiency, and financial management. The acquisition of Noramco and Extractas is expected to increase the company's guidance significantly. The net debt-to-EBITDA ratio stands at 1.0x, giving the company financial flexibility for future investments. The company's balance sheet is solid, and the Board of Directors has decided to increase the distribution to shareholders.
Outlook and Guidance
The company expects high single-digit growth in Drug Products and low single-digit growth in Drug Substance for 2026. The group is expected to grow at a low single-digit rate, with a core EBITDA margin above 23%. The company is confident in its ability to deliver on its guidance and outpace market growth. The momentum in Drug Products is significant, and the company is well-positioned to capture the trend in protein degraders.
Valuation Metrics
Using the current valuation metrics, the company's P/E Ratio stands at 20.49, and the EV/EBITDA ratio is 12.96. The ROE is 15.68%, indicating a strong return on equity. The Net Debt / EBITDA ratio is 1.56, which is relatively low. Analysts estimate next year's revenue growth at 9.1%, which is slightly higher than the company's guidance. Marcel Imwinkelried's statement that the company's focus is on profitable growth rather than just top-line sales growth reinforces the analysis that the company is on track to deliver strong financial performance.
Growth Prospects
The company's growth prospects are promising, driven by the acquisition of Noramco and Extractas, and the expected growth in Drug Products and protein degraders. The company's diversified portfolio and operational excellence are expected to contribute to its structural growth trajectory. The company's strong balance sheet and financial flexibility will enable it to pursue future investments and acquisitions.